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Interieukin-1-mediated Acute Lung Injury and
Tolerance to Oxidative Injury
John E. Repine
Webb-Waring Institute for Biomedical Research and the Department of Medicine atthe University of Colorado
Health Sciences Center, Denver, Colorado-
Interleukin-1 (IL-1) is a highly potent molecule that has a myriad of effects in biologic systems. This brief review describes some of our findings on
the effects of IL-1 in biologic systems. On the one hand, IL-1 treatment caused a neutrophil-dependent acute edematous lung injury that resembled
changes in the lungs of patients with the acute respiratory distress syndrome (ARDS). On the other hand, IL-1 pretreatment conferred a tolerance to
lung oxidative lung injury and ischemia-reperfusion insults-again conditions manifest in sick patients. The potential mechanisms responsible for
these seemingly paradoxical influences of IL-1 are described and related to possible strategies for the treatment of patients with ARDS, ischemia-
reperfusion disorders, and other oxidant-mediated conditions. - Environ Health Perspect 102(Suppl 10):75-78 (1994)
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Introduction
A delicate balance exists between oxidants
and antioxidants in health and disease.
This balance may be especially relevant to
lung physiology and pathophysiology. This
report briefly addresses the effects of inter-
leukin-I (IL-1) on this pivotal balance. We
examine both beneficial and detrimental
effects of IL-1 on oxidant-antioxidant sys-
tems. As part ofthe symposium on the role
of oxidants and antioxidants, this article
focuses largely on reviewing work that we
presented at the conference; the research of
other investigators will be presented first
hand elsewhere.
11-1-mediated Acute Lung
Injury
Acute noncardiogenic edematous lung
injury (often called the adult respiratory
distress syndrome or ARDS) is a highly
fatal lung disorder that occurs after a vari-
ety of pulmonary and nonpulmonary
insults (1). The etiology ofARDS is largely
unknown and, accordingly, no specific
therapy is available for this devastating and
perplexing condition.
Considerable evidence has been com-
piled, however, that supports the hypothesis
that oxidants contribute to the develop-
ment of ARDS. I will briefly summarize
these findings:
ARDS patients have increased numbers of
neutrophils in their lungs that are power-
ful generators of02radicals in vitro (2).
* ARDS patients have numerous factors in
their blood or lung lavages that increase
neutrophil and alveolar macrophage 02
radical release in vitro (2,3).
* Neutrophils recovered from the blood or
lungs ofARDS patients are either more
or less active than neutrophils from con-
trol subjects-either case suggesting neu-
trophil activation (4,5).
* ARDS patients have increased levels of
xanthine oxidase (XO) in their blood
compared to that ofcontrol subjects (6).
* ARDS patients exhale increased amounts
of hydrogen peroxide (7) and have
increased levels of lipid peroxidation
products (8-10) and oxidized antipro-
teases (11) in their blood compared to
control subjects.
* Finally, ARDS patients have decreased
blood levels of glutathione (GSH) (12),
and, for unknown reasons, increased
blood levels ofmanganese superoxide dis-
mutase (MnSOD) and catalase (13).
IL-1 levels are substantially increased in
lung lavages from ARDS patients com-
pared to the negligible levels of IL-1 in
lavages from control subjects (14,15). In
addition, cultured alveolar macrophages
(AM) recovered from ARDS patients
release more IL-1 than AM from control
subjects (16). Combined with the effects
ofIL-1 on neutrophils in vitro, these obser-
vations led us to propose that increased
intraalveolar levels of IL-1 could cause
acute lung injury by a mechanism involv-
ing neutrophils and neutrophil-derived
oxidants. We proceeded to test this
hypothesis by administering IL-1 intratra-
cheally to rats. Our experimental protocol
involved intratracheal insufflation of 50 ng
ofIL-1-a dose comparable to levels mea-
sured in lavages from ARDS patients.
Approximately 4.5 hr later, IP2 - labeled
albumin was injected iv; 30 min later (5 hr
after IL-1 administration) rats were
sacrificed and the lungs were removed, per-
fused blood-free, and lavaged. The ratio of
the I125-labeled albumin recovered in lung
lavages to I125-labeled albumin concentra-
tions in blood was used as a measure of
lung injury. The number ofneutrophils in
lung lavages was assessed by direct counts
and measurement of myeloperoxidase
(MPO) activity (17). For some experi-
ments, neutrophils were depleted from the
blood by prior treatment with vinblastine.
We found that rats given intratracheal
IL-1 had increased lung leak and lung neu-
trophils compared to that of control rats
(Figure 1) (18). Lung leak and lung neu-
trophil accumulation were both dependent
on the dose of IL-1 given, with approxi-
mately 50 ng causing an optimal response.
In contrast to native IL-1, administration
of previously heated IL-1 did not increase
lung neutrophils or lung leak. Histologic
examination of lungs given IL-1 revealed
an increased lung cellularity involving neu-
trophils and an abnormal edematous process
characterized by perivascular cuffing.
To determine the contribution ofneu-
trophils to lung leak, we made rats neu-
tropenic by giving vinblastine 4 days before
IL-1 administration (18). Rats made
severely neutropenic with vinblastine and
then given IL-I intratracheally had consid-
erably less lung leak than control rats or
rats given vinblastine just 1 day before IL-1
-a regimen that undoubtedly has many of
the systemic effects ofvinblastine but does
not decrease circulating neutrophil counts.
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Figure 1. Lungs of rats given IL-1 intratracheally had
increased leak (A) and lavage neutrophils (B) compared
to control lungs [modified from figure in LZeff etal. (18)].
These studies suggest that neutrophils con-
tribute to the development of lung leak in
rats given IL-1 intratracheally.
A number ofstudies (19-23) were con-
ducted using interventions to ascertain the
mechanism ofinjury following IL-1 admin-
istration (Figures 2, 3). First, and not sur-
prisingly, we found that pretreatment with
the IL-1 receptor antagonist (IL-Ira) com-
pletely prevented lung leak and lung neu-
trophil influx in rats given IL-1
intratracheally (19). Second, treatment with
a variety ofantioxidant agents reduced lung
leak and lung neutrophil accumulation.
Reduction of lung leak occurred in rats
treated with N-acetylcysteine (NAC), an
agent that increases cellular GSH levels
(20); dimethyl sulfoxide (DMSO), a scav-
enger of hydroxyl radical (-OH) in vitro
(18); and manganese-superoxide dismutase
(MnSOD), a scavenger of 0-in vitro (18).
Third, treatment with liposomal encapsu-
lated prostaglandin El (PGEI), but not
empty liposomes or free PGE1, also
decreased leak in lungs of rats given IL-1
intratracheally (21). Rats given IL-1 and
then treated with IL-Ira, DMSO, Lip-
PGE1, NAC and MnSOD also had
decreased numbers oflung neutrophils com-
pared to control rats given IL-1 intratra-
cheally (Figure 3). Finally, vitamin E, an
inhibitor oflipid peroxidation in vitro, given
by supercritical fluid aerosol technique
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Figure 2. Effect of interventions on the development of
lung leak in rats given IL-1 intratracheally. Data modi-
fied from Leff etal. (18-20) and Hybertson etal.(23).
(22,23), also decreased lung leak in rats
given IL-I intratracheally. However, vitamin
E treatment did not decrease lung neu-
trophil accumulation (as assessed by lung
MPO analyses) in rats given IL-1 intratra-
cheally. Rats given IL-1 intratracheally also
exhaled more H202 and developed greater
lung oxidized glutathione (GSSG) concentra-
tions than untreated control rats. Treatment
with NAC, DMSO, and Mn-SOD reduced
both H202 exhalation and lung GSSG levels
in rats given IL-1 intratracheally (18).
These findings in intact rats were cor-
roborated by recent experiments in isolated
saline-perfused rat lungs (24,25). Briefly, we
found that intratracheal administration of
native, but not heated, IL-1 (or IL-8) caused
lung injury (reflected by increased lung
weights and lung Ficoll concentrations) in
rats perfused with purified human neu-
trophils compared to lungs given only IL-1
(or IL-8), lungs perfused only with neu-
trophils, and untreated control lungs
(24,25). The contribution of neutrophil-
derived 02 radicals was substantiated when
neutrophils previouslyheated at 480C for 10
min-a process that specifically inactivates
NADPH-oxidase activity and neutrophil 02
release-did not damage isolated lungs
given IL-1 intratracheally. In parallel, heated
neutrophils adhered and chemotaxed nor-
mallybut did not make 02 in vitro (24).
Taken en toto, these findings suggest
that oxygen radicals from neutrophils con-
tribute to acute edematous lung injury in
rats given IL-1 intratracheally. Thus, IL-1
can have detrimental effects.
11-1-mediated Tolerance to
Oxidative Injury
The aforementioned section indicates that
IL-I has negative effects on the lung, notably
increasing lung neutrophils and causing lung
leak. This section focuses on the possibility
that IL-1 can have a beneficial influence on
oxidative lung injury by increasing lung
antioxidant enzyme activity. The latter phe-
nomenon is known as tolerance.
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Figure 3. Effect of interventions on increases in lavage
neutrophils in rats given IL-1 intratracheally. Data modi-
fied from Leff etal. (18-20) and Hybertson etal. (23).
Frank and his colleagues made a
remarkable discovery when they found
that rats pretreated with endotoxin sur-
vived subsequent exposure to hyperoxia
(>95% 02), while untreated rats exposed
to hyperoxia died within 72 hr (26).
Endotoxin-induced protection against 02
toxicity was associated with increases in
lung antioxidant enzyme activity.
Subsequently, we reasoned that because
many ofthe effects ofendotoxin are medi-
ated by cytokines, such as tumor necrosis
factor a (TNFa) and IL-1, then cytokines
could also provide tolerance to oxygen
toxicity. We found that rats pretreated
with TNFa and IL-1 were completely
resistant to oxygen toxicity (27,28).
Analogous to the situation following pre-
treatment with endotoxin, all rats pre-
treated with TNFa and IL-1 survived
indefinitely (>144 hr) while untreated
control rats invariably died within 72 hr of
exposure to 100% 02 (Figure 4). More-
over, pretreatment with TNFa and IL-1
prevented lung GSSG level increases that
occurred in control rats subjected to
hyperoxia (27). The latter finding indi-
cates the antioxidant-enhancing effects of
cytokine pretreatment. Subsequently,
other investigators have confirmed these
findings and documented that treatment
with either TNFax or IL-1 alone is
sufficient to develop tolerance (29,30).
Furthermore, administration of IL-1
intratracheally induced tolerance, which
was also associated with increases in lung
antioxidant enzyme activity.
Although the mechanisms responsible
for tolerance, as well as the causal relation-
ship between tolerance and increases in
lung antioxidant enzyme activity, are not
yet clearly established, the following obser-
vations seem relevant (29-31):
Hearts isolated from rats previously
treated with endotoxin, IL-1 or TNFa
resist I/R and have increased myocardial
A. Survival at96hr B. Pleural effusion C. Lung GSSG
volumes levels
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Figure 4.When exposed continuously to 100% 02, rats
pretreated with TNFac and IL-1 had increased survival
(A), decreased pleural effusion volumes (B), and
decreased lung GSSG levels (C) compared to rats not
pretreated with TNFa and IL-1. Data modified from
Brown et al. (35).
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Figure 5. Myocardial neutrophils increased in rats
given IL-1 6 hr before compared to control rats. Data
modified from Brown et al. (35).
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Figure 6. Hearts from rats pretreated 36 hr before with
IL-1 had decreased injury and increased ventricular
developed pressure compared to hearts from untreated
control rats. Data modified from Brown et al. (35).
antioxidant enzyme activities (34-36).
This generalizes the tolerance phenomena
to another organ and another oxidative
insult, I/R, which appears to involve xan-
thine oxidase (XO) activity.
* Six hours after IL-1 pretreatment, rat
hearts developed a neutrophil-dependent,
oxidative stress (increased myocardial
GSSG levels). This low-grade insult was a
necessary precursor for the subsequent
development of IL-I-induced tolerance
to I/R (Figure 5,6) (35). This finding is
consistent with the premise that a smaller
antecedent oxidative stress can increase
antioxidant enzyme activity and stimulate
resistance to a larger, subsequent oxida-
tive insult.
* Myriad studies using a variety ofcultured
cells, including lung endothelial cells,
support these relationships in simpler in
vitro systems (37-40). Moreover, there is
new evidence that synergy may exist with
respect to the induction oftolerance. For
example, IL-6 facilitates IL-I- induced
tolerance (41).
* The initial evidence linking tolerancewith
increases in antioxidant enzyme was the
observation that endotoxin-pretreated rats
given diethyldithiocarbamate (DDC), a
copper chelator and an inhibitor of
Cu,Zn-SOD, were not resistant to oxygen
toxicity (26). This finding established a
role for Cu,Zn-SOD in endotoxin-
induced tolerance to hyperoxic lung
injury. A second link was revealed in rats
given IL-1 (35). In this case, co-treatment
with aminonicotinamide reduced glucose-
6-phosphate dehydrogenase (G6-PD)
enzyme activity increases and abrogated
the associated protection to I/R in hearts
from rats pretreated with IL-1.
* In all cases, tolerance only occurs 24 hr
or more following treatment. Rats given
endotoxin or IL-I just 1 hr before or dur-
ing the challenge were not resistant to
I/R. This suggests that tolerance depends
on new protein synthesis and thus distin-
guishes tolerance from the precondition-
ing response (42). In the preconditioning
situation, brief episodes of I/R rapidly
made hearts resistant to subsequent I/R
episodes. The preconditioning phenome-
non is also distinguishable from tolerance
because it does not appear to involve
increases in antioxidant enzyme activity.
In summary, there is substantial evi-
dence in animal and in vitro systems that
implicates a tolerance response involving,
but perhaps not limited to, increases in
antioxidant enzyme activity. This tolerance
response could occur in some patients with
ARDS. Notably, blood Mn-SOD and cata-
lase activities were increased in septic
patients who developed ARDS compared
to both septic patients who did not
develop ARDS and control subjects. It is
not known why these levels were increased
but ifthey do not simply reflect cell dam-
age, they might reflect a tolerance reaction.
Even though these responses did not pre-
vent ARDS, they might have altered the
course, frequency, or severity ofthe disease.
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Figure 7. "Yin-Yang" responses to IL-1 in biological
systems. On the one hand, IL-1 can cause an oxidative
lung injury. On the other hand, IL-1 can increase cata-
lase and prevent oxidative lung injury.
Alternatively, increased catalase or SOD
activities may paradoxically increase lipid
peroxidation (43,44) and contribute to tis-
sue damage. Furthermore, it remains per-
plexing that only a small fraction of
patients with apparently similar insults
develop ARDS. Could this reflect toler-
ance, or perhaps an ineffective tolerance
response, because of genetic or acquired
circumstances?
Conclusions
This briefarticle presents two cases (Figure
7). The first implicates IL-I as a cause ofa
neutrophil-dependent acute oxidative lung
injury. The second points to IL-1 as a
potential mediator of a tolerance process
that confers protection against oxidant-
induced lung injury, at least in part, by
increasing lung antioxidant enzyme activ-
ity. When taken at face value, these two
processes predict a conflicting set ofevents
that are likely to significantly affect the
course ofARDS. Additional information is
necessary before the relative merits ofthese
apparently competing systems can be
understood and appreciated fully. Needless
to say, this information should be obtained
and would be extremely valuable for
designing and evaluating the results ofclin-
ical trials that will use various antiendo-
toxin and anticytokine (e.g., IL-Ira,
soluble TNFa receptors and CT1501R)
therapies to treat patients with ARDS.
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